Date: May 05, 2001 Source: PR Newswire (
click here to go to the source)
PRINCETON, N.J., May 6 /PRNewswire/ -- Invenux, Inc., a privately held drug discovery company, announced today its participation in the
'Outpartnering and Outsourcing in Drug Discovery' conference, held in Princeton, NJ. The conference, held by IBC USA Life Sciences, served to highlight the integration of external technologies and services to make drug discovery faster and more efficient, and was attended by approximately 70 high-level representatives from the pharmaceutical industry.
Bruce Eaton, Professor of Chemistry at North Carolina State University,presented "Evolutionary Chemistry(TM) - Integrated Discovery and Optimization," in which he described the proprietary technology of Invenux, Inc. -- Evolutionary Chemistry(TM) -- stressing the integrated nature of this discovery platform. "The true integration of the compound synthesis component of drug discovery with the selection and optimization components is powerful, and unique to this technology. In addition, Evolutionary Chemistry(TM) enables the generation of libraries of 5 to 50 million compounds designed for the target of interest, as well as the real-time selection of the best compounds from these libraries."
Prof. Eaton, a Founder and Senior VP of Technology Advancement for Invenux, also presented data in which the proprietary drug discovery platform
of Invenux was applied to the discovery of new antibiotic lead compounds for Methicillin-resistant staphylococcus aureus (MRSA). The President and CEO of Invenux, Carl Pelzel, also spoke at the conference on the subject of "Fallen Angels: Innovative Ways to Derive Value from Failed Discovery
Programs." Attendees and presenters at the conference represented several related industries, from large pharmaceutical companies to biotech, CRO, service, and chemical genomic companies, highlighting across-the-board interest in novel schemes to integrate steps of the discovery process. These types of novel approaches will present more opportunities for outpartnering and outsourcing discovery solutions, allowing better and more efficient drug discovery collaborations.
Invenux, Inc.
Founded in February 2000, Denver-based Invenux, Inc. is a privately held drug discovery company utilizing proprietary, breakthrough technology that has the potential to deliver active, specific compounds for virtually any therapeutic target. Invenux's core technology is Evolutionary Chemistry(TM)
-- a technology that promises to significantly streamline the drug discovery process by selecting only the most promising leads from millions of compounds.
For more information, please visit www.invenux.com .
